Movement Alert｜Abivax S.A. Falls 5.47% in Regular Trading, H1 EPS Misses Estimates as Analysts Slash Price Targets

Market Focus

Sep 22

On September 22, Abivax S.A. fell 5.47% in regular trading, trading near $97.985 per share with turnover of approximately $28.76 million. The decline was triggered by a significant H1 earnings miss and subsequent analyst downgrades.

Abivax S.A. reported H1 losses of $(2.43) per share, missing the consensus estimate of $(1.08) by 125%, representing a 65.31% increase in losses compared with $(1.47) per share in the year-ago period. While revenue of $2.959 million beat the $1.860 million estimate, the widening loss weighed heavily on sentiment. In response, Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating, and Truist lowered its target to $151. The average analyst price target now stands at $164.20.

Separately, Abivax S.A. announced a chief medical officer transition, with Chris Rabbat set to succeed Fabio Cataldi in Q4. The company continues advancing its NDA submission for obefazimod in ulcerative colitis, targeted for year-end, and closed a $920 million ADS offering in July to fund operations into Q4 of 2029.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/news/1167433189"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167433189\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167433189?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167433189","market":"us","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Falls 5.47% in Regular Trading, H1 EPS Misses Estimates as Analysts Slash Price Targets","media":"Market Focus","content":"<p><p>On September 22, Abivax S.A. fell 5.47% in regular trading, trading near $97.985 per share with turnover of approximately $28.76 million. The decline was triggered by a significant H1 earnings miss and subsequent analyst downgrades.</p><p>Abivax S.A. reported H1 losses of $(2.43) per share, missing the consensus estimate of $(1.08) by 125%, representing a 65.31% increase in losses compared with $(1.47) per share in the year-ago period. While revenue of $2.959 million beat the $1.860 million estimate, the widening loss weighed heavily on sentiment. In response, Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating, and Truist lowered its target to $151. The average analyst price target now stands at $164.20.</p><p>Separately, Abivax S.A. announced a chief medical officer transition, with Chris Rabbat set to succeed Fabio Cataldi in Q4. The company continues advancing its NDA submission for obefazimod in ulcerative colitis, targeted for year-end, and closed a $920 million ADS offering in July to fund operations into Q4 of 2029.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Falls 5.47% in Regular Trading, H1 EPS Misses Estimates as Analysts Slash Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Falls 5.47% in Regular Trading, H1 EPS Misses Estimates as Analysts Slash Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-22 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 22, Abivax S.A. fell 5.47% in regular trading, trading near $97.985 per share with turnover of approximately $28.76 million. The decline was triggered by a significant H1 earnings miss and subsequent analyst downgrades.</p><p>Abivax S.A. reported H1 losses of $(2.43) per share, missing the consensus estimate of $(1.08) by 125%, representing a 65.31% increase in losses compared with $(1.47) per share in the year-ago period. While revenue of $2.959 million beat the $1.860 million estimate, the widening loss weighed heavily on sentiment. In response, Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating, and Truist lowered its target to $151. The average analyst price target now stands at $164.20.</p><p>Separately, Abivax S.A. announced a chief medical officer transition, with Chris Rabbat set to succeed Fabio Cataldi in Q4. The company continues advancing its NDA submission for obefazimod in ulcerative colitis, targeted for year-end, and closed a $920 million ADS offering in July to fund operations into Q4 of 2029.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1167433189","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167433189","pubTimestamp":1790084838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 22, Abivax S.A. fell 5.47% in regular trading, trading near $97.985 per share with turnover of approximately $28.76 million. The decline was triggered by a significant H1 earnings miss...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"走势警报|Abivax S.A. 常规交易中下跌 5.47%，分析师下调目标价，上半年每股收益未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On September 22, Abivax S.A. fell 5.47% in regular trading, trading near $97.985 per share with turnover of approximately $28.76 million. The decline was triggered by a significant H1 earnings miss and subsequent analyst downgrades.Abivax S.A. reported H1 losses of $(2.43) per share, missing the consensus estimate of $(1.08) by 125%, representing a 65.31% increase in losses compared with $(1.47) per share in the year-ago period. While revenue of $2.959 million beat the $1.860 million estimate, the widening loss weighed heavily on sentiment. In response, Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating, and Truist lowered its target to $151. The average analyst price target now stands at $164.20.Separately, Abivax S.A. announced a chief medical officer transition, with Chris Rabbat set to succeed Fabio Cataldi in Q4. The company continues advancing its NDA submission for obefazimod in ulcerative colitis, targeted for year-end, and closed a $920 million ADS offering in July to fund operations into Q4 of 2029.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}